These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9444438)

  • 1. Calcium channel blockers: association with myocardial infarction, mortality, and cancer.
    Cheng JW; Behar L
    Clin Ther; 1997; 19(6):1255-68; discussion 1253-4. PubMed ID: 9444438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The calcium channel blocker controversy.
    Kaplan NM
    Hypertens Res; 1996 Jun; 19(2):57-64. PubMed ID: 10968196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of calcium channel blockers and myocardial infarction in hypertensive patients with rheumatoid arthritis - A nationwide cohort study.
    Lin TT; Ko TY; Lin LY; Wu CK
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):350-358. PubMed ID: 31257076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.
    Jeffers BW; Robbins J; Bhambri R
    Am J Ther; 2017; 24(1):e68-e80. PubMed ID: 26588586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
    Opie LH; Yusuf S; Kübler W
    Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis.
    Bangalore S; Parkar S; Messerli FH
    Am J Med; 2009 Apr; 122(4):356-65. PubMed ID: 19332231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
    Opie LH
    Am J Hypertens; 1997 May; 10(5 Pt 1):565-77. PubMed ID: 9160770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
    Kloner RA; Vetrovec GW; Materson BJ; Levenstein M
    Am J Cardiol; 1998 Jan; 81(2):163-9. PubMed ID: 9591899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers in cardiovascular pharmacotherapy.
    Godfraind T
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of calcium-channel blockers.
    Massie BM
    Clin Cardiol; 1998 Dec; 21(12 Suppl 2):II12-7. PubMed ID: 9853194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers for hypertension.
    Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of calcium channel blockers in cardiovascular risk reduction: issues in Latin America.
    Alcocer L; Bendersky M; Acosta J; Urina-Triana M
    Am J Cardiovasc Drugs; 2010; 10(3):143-54. PubMed ID: 20524716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies concerning calcium antagonists.
    Lichtlen PR
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):409-12. PubMed ID: 8924053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy.
    Opie LH; Schall R
    J Am Coll Cardiol; 2002 Jan; 39(2):315-22. PubMed ID: 11788225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers in the dock: innocent or guilty?
    Mackay JA; Sever PS
    J Hum Hypertens; 1996 May; 10(5):277-80. PubMed ID: 8817399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.
    Braun S; Boyko V; Behar S; Reicher-Reiss H; Laniado S; Kaplinsky E; Goldbourt U
    J Am Coll Cardiol; 1998 Mar; 31(4):804-8. PubMed ID: 9525550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers as initial therapeutic agents in hypertension: relationship to incident heart failure.
    Shields DL
    Biol Res Nurs; 2014 Jul; 16(3):266-77. PubMed ID: 23864228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.